Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Propagermanium · 2 trials · 2 indications
Assessed by monitoring of adverse events
Assessed by measuring albumin/creatinine ratio.
| Arm | Type | Description |
|---|---|---|
| Propagermanium then Placebo | EXPERIMENTAL | Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary. Participants will receive 16 weeks propagermanium and 16 weeks placebo separated by a 6 week washout period. |
| Placebo then Propagermanium | EXPERIMENTAL | Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary. Participants will receive 16 weeks placebo and 16 weeks propagermanium separated by a 6 week washout period. |
| Name | Type | Description |
|---|---|---|
| Propagermanium | DRUG | Immediate release capsule |
| Placebo | DRUG | Placebo capsule |
Inclusion Criteria: 1. Aged 18 to 80 (inclusive) at screening; 2. A diagnosis of primary FSGS confirmed by renal biopsy; 3. Must be receiving a stable dose of 300 mg daily dose of irbesartan (in any marketed formulation) for at least 3 months prior to screening, and have no plan to change treatment...
Propagermanium is an investigational small molecule being studied for Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis. It is in Phase 2 clinical development. It is not approved by the FDA and remains under investigation for these kidney conditions.
Propagermanium is being developed by IQVIA Holdings, Inc., which trades under the ticker IQV. The company is conducting clinical trials for the drug in nephrology indications.
Propagermanium is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Clinical trials for the drug have been completed, and it is not currently in active trials.
Propagermanium has been studied in two completed Phase 2 trials. NCT03627715 evaluated the drug in Diabetic Kidney Disease participants receiving Irbesartan, with 45 enrolled. NCT03649152 evaluated it in Focal Segmental Glomerulosclerosis participants receiving Irbesartan, with 8 enrolled.
No alternative names for Propagermanium have been reported. The drug is referred to by its generic name, Propagermanium, in clinical trial records and development documentation.